{"analyses":[{"estimateComment":"A normal score \\< 0 indicates fewer than expected events for the panitumumab plus BSC arm and therefore a longer time to event.","groupDescription":"PFS in the ITT Analysis Set was tested at a significance level of 5% conditional on a significant treatment effect on overall survival in the ITT Analysis Set.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","paramType":"Normal score","paramValue":"-6.08","statisticalComment":"Log-rank test stratified by randomization factors: geographic region (Europe vs Asia vs rest of world) and ECOG performance status (0 or 1 vs 2).","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.4","upperLimit":"5.3","value":"3.6"},{"groupId":"OG001","lowerLimit":"1.6","upperLimit":"1.9","value":"1.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"189"},{"groupId":"OG001","value":"188"}],"units":"Participants"}],"description":"Progression-free survival (PFS) was defined as the time from the randomization date to the date of disease progression per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 or death. Progressive disease (PD): At least a 20% increase in the size of target lesions compared with the smallest size since treatment started and an absolute increase of at least 5 mm, any new lesions or an increase in size of non-target lesions thought be ≥ 20% and an absolute increase of at least 5 mm, or significant increase in pleural effusions, ascites or other fluid collections with cytologic proof of malignancy. Participants who were alive and did not meet the criteria for progression by the analysis data cut-off date were censored at their last evaluable disease assessment date.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received panitumumab administered intravenously 6 mg/kg every 14 days plus best supportive care (BSC) until disease progression, withdrawal of consent, death, or intolerance of study drug.","id":"OG000","title":"Panitumumab + BSC"},{"description":"Participants received best supportive care until disease progression, withdrawal of consent, or death.","id":"OG001","title":"BSC Alone"}],"paramType":"MEDIAN","populationDescription":"ITT Analysis Set","reportingStatus":"POSTED","timeFrame":"From randomization to the last on-study or long-term follow-up visit, as of the data cut-off date of 10 June 2014. The median follow-up time was 34.9 weeks (panitumumab plus BSC: 41.0 weeks; BSC alone: 25.5 weeks).","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"months"}